This site is intended for healthcare professionals
A close up image of a microscope
  • Home
  • /
  • Clinical trials
  • /
  • Menopause
  • /
  • Silicone Gel vs. Estrogen Vaginal Cream for the Ma...
Clinical trial

Silicone Gel vs. Estrogen Vaginal Cream for the Management of Genitourinary Syndrome of Menopause (VITAL-E)

Read time: 1 mins
Last updated:18th Mar 2024
Status: RECRUITING
Identifier: NCT05672901
Silicone Gel vs. Estrogen Vaginal Cream for the Management of Genitourinary Syndrome of Menopause (VITAL-E)


ClinicalTrials.gov ID: NCT05672901
Sponsor: Stratpharma AG
Information provided by: Stratpharma AG (Responsible Party)
Last Update Posted: 2023-04-07

Brief Summary:

The goal of this randomized controlled trial is to test the efficacy of StrataMGT in the management of Genitourinary Syndrome of Menopause (GSM) compared to estrogen therapy. The main question it aims to answer is:
- Will StrataMGT be non-inferior regarding patient quality of life compared to standard of care?

Participants will use either StrataMGT or estrogen vaginal cream to treat GSM for 3 consecutive months. After the baseline assessment, participants will be assessed monthly for quality of life, clinical signs, symptoms, pathology and adverse reactions.

Official Title:
Comparison of a Novel Silicone Gel vs. Estrogen Vaginal Cream for the Management of Genitourinary Syndrome of Menopause: a Non-inferiority Trial

Intervention / Treatment:
- Device: StrataMGT
- Drug: Estrace 0.01% Vaginal Cream

Category Value
Study Start (Actual) 2023-03-27
Primary Completion (Estimated) 2024-06
Study Completion (Estimated) 2024-06
Enrollment (Estimated) 100
Study Type Interventional
Phase Phase 3
Other Study ID Numbers
SPAMG02


View full details